FDA Inspection 1271067 — Cayman Pharma s.r.o.

Cayman Pharma s.r.o. — FEI 3003625059

The FDA completed an inspection of Cayman Pharma s.r.o. on July 28, 2022 in Neratovice. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
July 28, 2022
Fiscal Year
2022
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Neratovice (Czech Republic)

Additional Details

Mutual Recognition Agreement (MRA)